DSIP
unknown riskAlso: Delta Sleep-Inducing Peptide · DSIP nonapeptide
DSIP is a neuropeptide first isolated from rabbit brain venous blood in 1974, originally identified by its ability to induce slow-wave sleep. It has shown anxiolytic, stress-modulating, and opiate withdrawal-alleviating properties in human studies.
Reported Benefits
Sleep Quality
Original human studies demonstrated increased slow-wave sleep and reduced sleep latency.
Opiate Withdrawal
Swiss and Russian trials show alleviation of withdrawal symptoms.
Stress Reduction
Modulates ACTH/cortisol response to stress in human studies.
Mechanism of Action
DSIP crosses the blood-brain barrier and modulates multiple neurotransmitter systems. It reduces ACTH and beta-endorphin release under stress, modulates serotonergic and dopaminergic activity, and has been proposed to regulate the circadian oscillator through prostaglandin pathways.
Key Clinical Studies
Graf MV and Kastin AJ (1986)
review · Review of 23 studies
DSIP reduces sleep latency and increases SWS across multiple protocols
Ruigt GS et al. (1984)
crossover RCT · 10 healthy subjects
DSIP administered IV increased slow-wave sleep fraction
Overview
DSIP was among the first neuropeptides investigated for potential therapeutic application, with research spanning from its discovery in 1974 through the 1980s and 1990s. While sleep induction was the original focus, the broader evidence base reveals a stress-modulating neuropeptide with multiple potential applications.
The Opiate Withdrawal Application
The most compelling human evidence for DSIP is in opiate withdrawal. Swiss studies in the 1980s-90s showed that IV DSIP significantly reduced withdrawal severity scores, potentially through modulation of the HPA axis and endogenous opiate systems. This application is mechanistically distinct from sleep induction.
Circadian Modulation
DSIP has been proposed to function as a circadian pacemaker modulator — influencing not just sleep initiation but the underlying biological clock. If confirmed, this would distinguish it from conventional hypnotics and position it closer to melatonin in mechanism.
Current Status
Modern pharmaceutical development essentially abandoned DSIP in favor of other sleep/anxiety targets (orexin antagonists, GABA modulators). However, it remains available as a research peptide and attracts ongoing interest in biohacking and longevity communities.
Regulatory Status
Research OnlyNot FDA-approved; primarily Soviet/European research
Safety Profile
Side Effects
- •Headache (mild)
- •Hypotension (IV, at high doses)
Contraindications
- •Active neurological disease
Drug Interactions
- •Opiates (synergistic for withdrawal use)
- •CNS depressants
Primary Uses
Weekly Briefing
Regulatory updates + new study breakdowns.
For Practitioners
Do you prescribe DSIP?
Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.
Get Listed →